These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Variations of ferritin levels over a period of 15 years as a compliance chelation index in thalassemic patients. Kattamis A; Dinopoulos A; Ladis V; Berdousi H; Kattamis C Am J Hematol; 2001 Dec; 68(4):221-4. PubMed ID: 11754409 [TBL] [Abstract][Full Text] [Related]
25. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients. Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264 [TBL] [Abstract][Full Text] [Related]
26. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone. Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of cardiac function in patients with thalassemia major. Nienhuis AW; Griffith P; Strawczynski H; Henry W; Borer J; Leon M; Anderson WF Ann N Y Acad Sci; 1980; 344():384-96. PubMed ID: 6930878 [TBL] [Abstract][Full Text] [Related]
28. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients. Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580 [TBL] [Abstract][Full Text] [Related]
29. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Daar S; Pathare AV Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126 [TBL] [Abstract][Full Text] [Related]
30. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Borgna-Pignatti C; Rugolotto S; De Stefano P; Zhao H; Cappellini MD; Del Vecchio GC; Romeo MA; Forni GL; Gamberini MR; Ghilardi R; Piga A; Cnaan A Haematologica; 2004 Oct; 89(10):1187-93. PubMed ID: 15477202 [TBL] [Abstract][Full Text] [Related]
31. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Piga A; Gaglioti C; Fogliacco E; Tricta F Haematologica; 2003 May; 88(5):489-96. PubMed ID: 12745268 [TBL] [Abstract][Full Text] [Related]
33. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators. Kolnagou A; Kontoghiorghes GJ Hemoglobin; 2006; 30(2):239-49. PubMed ID: 16798649 [TBL] [Abstract][Full Text] [Related]
34. [Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major]. Flückiger A; Imbach P; Pfenninger E; Stocker F; Töndury P; Wagner HP; Weber J; Zuppinger K Helv Paediatr Acta; 1985 Sep; 40(4):293-304. PubMed ID: 4077563 [TBL] [Abstract][Full Text] [Related]
35. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547 [TBL] [Abstract][Full Text] [Related]
36. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience. Peng CT; Tsai CH; Wu KH Hemoglobin; 2008; 32(1-2):49-62. PubMed ID: 18274983 [TBL] [Abstract][Full Text] [Related]
37. Combined subcutaneous and high-dose intravenous deferoxamine therapy of thalassemia. Hyman CB; Agness CL; Rodriguez-Funes R; Zednikova M Ann N Y Acad Sci; 1985; 445():293-303. PubMed ID: 3860133 [TBL] [Abstract][Full Text] [Related]
39. Could chelation therapy with deferoxamine enhance the percentage of responders to interferon therapy in chronic hepatitis C? Leonardi S; Musumeci S Acta Haematol; 1993; 90(4):211-2. PubMed ID: 8140864 [No Abstract] [Full Text] [Related]
40. Response to long-term deferoxamine therapy in thalassemia. Cohen A; Martin M; Schwartz E J Pediatr; 1981 Nov; 99(5):689-94. PubMed ID: 7299539 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]